Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Elamipretide→

Elamipretide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
736992-21-5
Molecular formula
C32H49N9O5
Molecular weight
639.79 g/mol
Drug class
Mitochondria-targeted tetrapeptidecardiolipin-binding mitochondrial modulator
Mechanism of action
Binds cardiolipin in the inner mitochondrial membrane and localises to the inner mitochondrial membrane, where it is intended to improve mitochondrial structure and function. The clinical mechanism underlying increased muscle strength in Barth syndrome is not fully established.
Indications / reported uses
  • To improve muscle strength in adult and paediatric patients with Barth syndrome weighing at least 30 kg under the US FDA FORZINITY accelerated-approval indication (September 19 2025)

Sources: US DailyMed — FORZINITY (elamipretide), updated December 10 2025 · US FDA — FORZINITY accelerated approval · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Elamipretide Environmental Risk Assessment (ERA) (the Elamipretide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.